Table 5 Predictors of clinical disease among participants with CBD at baseline
From: Long-term follow-up of beryllium sensitized workers from a single employer
Baseline Characteristics | WITHOUT clinical CBD at follow-up n = 15 | WITH clinical CBD at follow-up n = 7* | P value |
|---|---|---|---|
Age in years (s.d.) | 45.6 (9.27) | 52.6 (12.0) | 0.15 |
Race (% white) | 93 | 100 | 0.48 |
Sex (%male) | 73 | 86 | 0.52 |
History of hay fever, asthma or eczema % | 47 | 57 | 0.65 |
Mean length from hire date to baseline evaluation, in years (s.d) | 13.7 (5.9) | 13.9 (9.4) | 0.95 |
Period of beryllium exposure, in years (s.d) | 18.6 (8.1) | 16.6 (9.7) | 0.61 |
Time from baseline to follow-up evaluation(s.d) | 8.3 (2.9) | 7.7 (4.4) | 0.70 |
Baseline PFTs (% predicted (s.d.)) | Â | Â | Â |
FEV1 | 87.5 (16.3) | 83.4 (18.3) | 0.60 |
FVC | 91.2 (12.2) | 83.7 (9.3) | 0.17 |
FEV1/FVC | 95.9 (13.1) | 92.9 (9.9) | 0.60 |
DLCO | 98.1 (23.9) | 104.3 (22.0) | 0.59 |
TLC | 95.8 (17.2) | 92.4 (9.0) | 0.64 |
Follow-up Characteristics | Â | Â | Â |
Smoking Status | Â | Â | Â |
Nonsmoker % | 40 | 29 | Â |
Ex smoker % | 47 | 71 | 0.44 |
Current smoker % | 13 | 0 | Â |
% still working at beryllium facility | 27 | 14 | 0.52 |
BeLPT results * | Â | Â | Â |
(+/+) | 40 | 50 | Â |
(+/-) | 33 | 33 | 0.89 |
(-/-) | 27 | 17 | Â |
* result for 1 person was missing | Â | Â | Â |